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Abstract
Background: Assumptions about survival of HIV-infected children in Africa without antiretroviral therapy need to be
updated to inform ongoing UNAIDS modelling of paediatric HIV epidemics among children. Improved estimates of infant
survival by timing of HIV-infection (perinatally or postnatally) are thus needed.
Methodology/Principal Findings: A pooled analysis was conducted of individual data of all available intervention cohorts and
randomized trials on prevention of HIVmother-to-child transmission in Africa. Studies were right-censored at the time of infant
antiretroviral initiation. Overall mortality rate per 1000 child-years of follow-up was calculated by selected maternal and infant
characteristics. The Kaplan-Meier method was used to estimate survival curves by child’s HIV infection status and timing of HIV
infection. Individual data from 12 studies were pooled, with 12,112 children of HIV-infected women. Mortality rates per 1,000
child-years follow-up were 39.3 and 381.6 for HIV-uninfected and infected children respectively. One year after acquisition of
HIV infection, an estimated 26% postnatally and 52% perinatally infected children would have died; and 4% uninfected
children by age 1 year. Mortality was independently associated with maternal death (adjusted hazard ratio 2.2, 95%CI 1.6–3.0),
maternal CD4,350 cells/ml (1.4, 1.1–1.7), postnatal (3.1, 2.1–4.1) or peri-partum HIV-infection (12.4, 10.1–15.3).
Conclusions/Results: These results update previous work and inform future UNAIDS modelling by providing survival
estimates for HIV-infected untreated African children by timing of infection. We highlight the urgent need for the
prevention of peri-partum and postnatal transmission and timely assessment of HIV infection in infants to initiate
antiretroviral care and support for HIV-infected children.
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Introduction
Sub-Saharan Africa remains the region most heavily affected by
HIV. In 2008, an estimated 1,800,000 HIV-infected children
under 15 years were living in sub-Saharan Africa, and this
continent accounted for 91% of new HIV infections among
children [1]. While it is important to have accurate estimates of
survival when children are treated with antiretroviral therapy,
assumptions about survival of HIV-infected children in Africa in
the absence of treatment [2,3] need to be updated and refined to
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inform ongoing UNAIDS modelling of HIV epidemiology among
children. For this purpose, UNAIDS convened a working group to
attempt to pool data from all available clinical trials on mother-to-
child HIV transmission prevention conducted in sub-Saharan
Africa over the last 15 years, to reliably assess mortality rates in
HIV-infected children.
More specifically, precise estimates of infant survival by timing
of HIV-infection (perinatally or postnatally through breastfeeding)
are urgently needed. Such estimates will provide benchmarks for
assessing the impacts of paediatric HIV treatment whilst allowing
for the effect of background mortality on survival post-infection of
children. We here present the results based on data with consistent
information on timing of acquisition of infection, both before or
during delivery, and postnatally to reliably estimate infant survival
by timing of HIV-infection. We update the previously conducted
individual patient meta-analysis on survival in HIV-exposed
children [3] which had limited statistical power especially on the
timing of acquisition of infection.
Methods
Studies eligible for this pooled analysis were clinical trials or
cohort studies in sub-Saharan African countries that investigated
the effect of antiretroviral-based and/or infant feeding interven-
tions in risk reduction of HIV vertical transmission with paediatric
follow-up for 18–24 months and information about infant feeding.
Overall, 18 trials and cohort studies aimed at the prevention of
mother-to-child transmission of HIV in African settings were
eligible for this pooled analysis and contacted (Figure 1). Of these,
four teams did not want to participate or could not share the data
at the time of the analysis [4,5,6,7], two datasets were excluded
(missing key variables) [8,9], and 12 provided the necessary data
[10,11,12,13,14,15,16,17,18,19,20,21]. The PRISMA checklist is
available as supporting information; see Checklist S1.
Paediatric HIV infection was defined as a positive plasma HIV-
1 DNA/RNA PCR at any age. Children with a positive HIV-1
diagnostic test result before 4–6 weeks of age (depending on the
timing of collection of blood samples in each study) were
considered to be HIV-infected in peri-partum [22,23]. This
includes infants infected in utero and DNA/RNA positive on the
day of birth. Children with a negative DNA/RNA PCR from a
sample obtained at or after 4–6 weeks of age who subsequently
acquired infection were considered to be HIV-infected postnatally
[22,23]. Children with positive test results at or after 4–6 weeks of
age but with either no previous negative test result, or last negative
test result before 4–6 weeks were considered infected with
unknown timing of infection [22,23].
Antiretroviral treatment became available to children in the
Mashi trial on the first of October 2002, so follow-up was rightly
censored at this point. Infant antiretroviral treatment was not
available during the time of the other trials. Maternal antiretro-
viral treatment was available in the Mitra Plus study only.
Baseline characteristics were described for each study included in
the pooled analysis. Overall mortality as a rate per 1000 child-years
of follow-up was calculated by selected maternal and infant
characteristics. The Kaplan-Meier method was used to estimate
survival curves among HIV-infected children: children infected in
peri-partum, infected in postnatal, and infected with unknown
timing of infection. Estimated time of diagnosis of HIV-infection for
those infected postnatally was taken as mid-way between the last
HIV-negative test and the first HIV-positive test. The survival of
children infected peri-partum or with unknown timing was estimated
from birth. Studies were right-censored at the time of infant
antiretroviral initiation. We used random-effects Weibull regression
models to estimate mortality hazard ratios accounting for heteroge-
neity between trials and cohorts. Adjusted hazard ratios were
obtained, both overall and for HIV-uninfected and HIV-infected
children separately. The multivariable models included the following
variables: region of origin (South Africa, East Africa, West Africa),
sex (boys, girls, unknown), maternal vital status (time-varying: alive,
dead), antenatal maternal CD4 count in cells/ml ($350, ,350,
unknown), breastfeeding practice in the first year of life (ever, never),
and child HIV-infection status (uninfected, determined infected in
peri-partum, infected postnatally, infected with unknown timing).
Age at time of infection was allowed for in the model.
Results
The characteristics of the datasets included in the first step
analysis are detailed in Table 1 and Table 2. Overall 12,112
infants born to HIV-infected mothers were included. Children
with unknown HIV status were excluded from the analysis
(n = 639). Analysis was therefore conducted among uninfected
children (n= 8,964) and HIV-infected (n= 2,509, HIV infection
acquired perinatally, through breastfeeding, or with unknown
timing).
Overall, 1,363 children acquired infection perinatally with
median time of first positive DNA/RNA test at 19 days
(interquartile range: 1–42 days), 581 children were negative at
or after 4 weeks of age and acquired infection through
breastfeeding at a median 24 weeks of age (interquartile range:
7–39 weeks), and 565 children were infected with unknown timing
of infection and had a first positive DNA/RNA test at 80 days in
median (interquartile range: 51–168 days).
Crude mortality rates per 1,000 child-years of follow-up were
39.3 and 381.6 for HIV-uninfected and HIV-infected children,
respectively. Mortality rate per 1000 child-years of follow-up by
selected maternal and infant characteristics are detailed in Table 3.
Mortality was estimated for HIV-infected children by timing of
transmission; initial time was the estimated date of acquisition of
HIV-infection (Figure 2). Overall, 12 months post-acquisition of
infection, an estimated 52% of children with peripartum infection
(95% confidence interval [CI]: 49–55%) and 26% (95% CI: 22–
31%) of those with postnatal infection died. Among children with
unknown timing, an estimated 38% (95% CI: 22–31%) died
compared with an estimated 4% of uninfected children who died
by age 1 year. Detailed probabilities are available as supporting
information; see Table S1.
Adjusted mortality hazard ratios (aHR) with 95% CI by selected
characteristics were estimated in regression analyses among HIV-
infected and uninfected children (n = 11,473). With South Africa
as reference, mortality was significantly higher in East Africa, aHR
1.41 (1.14–1.74), but not West Africa, aHR 1.20 (0.88–1.63).
Mortality did not differ significantly by sex: with boys as reference,
aHR in girls was 1.02 (0.76–1.36). When the mother died during
follow-up, children were more than twice likely to die (aHR 2.21
(1.63–3.00)) than when mothers survived. With mothers with
CD4$350 cells/ml as reference, children born to women with
CD4,350 (aHR 1.36 (1.08–1.71)) or to women with unknown
CD4 (aHR 1.30 (0.72–2.37)) were at significantly increased risk of
dying. Children who had never been breastfed were at more than
double the risk of dying than ever breastfed children (aHR 2.21
(1.62–3.01)). Mortality was substantially and significantly associ-
ated with child HIV infection status: compared to uninfected
children, the aHRs were 12.45 (10.15–15.27) for perinatally
infected children, 3.08 (2.29–4.14) for children infected through
breastfeeding and 7.21 (5.53–9.39) for children with unknown
timing of infection.
Infant Survival by Timing of HIV-Infection
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Discussion
Mortality of children born to HIV-infected mothers was
assessed on a large dataset from three different regions in sub-
Saharan Africa. Overall mortality of HIV-infected children was
dramatically elevated, irrespective of timing of acquisition of
infection. However, among HIV-infected children, survival from
acquisition of infection in postnatally infected children was higher
than in those with infection acquired around delivery: the 18-
month post-infection mortality risks were 36% (30%–42%) and
60% (57%–63%), respectively. Most these children had been
included in research studies offering relatively high standard of
care compared to less supported field areas; a closed clinical
follow-up adapted to the child’s age with free provision of care was
provided to these children. Hence, we assume the survival
estimates presented here were higher than what would be expected
in more operational field settings. Our results are in accordance
with previous findings of high mortality in vertically-infected
children [24]: more than half of these children will have died by
age two years. While the previously conducted meta-analysis on
the subject had limited statistical power to assess infant mortality
according to the timing of acquisition of HIV infection, we here
present more reliable estimates on this matter.
Our analysis strategy implied that the survival was assessed from
the estimated timing of infection in order to assess survival after
infection for perinatally and postnatally infected children. This
Figure 1. The PRISMA flow chart showing the progress of trials through the review.
doi:10.1371/journal.pone.0028510.g001
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Table 1. Characteristics of the mother-infant pairs included in the pooled analysis (first generation studies, before year 2000).
ANRSa Ditrame
Trial, Coˆte
d’Ivoire, Burkina
Faso (Dabis
Lancet 99)
ANRSb Ditrame
Trial, Burkina
Faso, Coˆte
d’Ivoire (Msellati
Sex Transm
Infect 99)
Nairobi Trial,
Kenya (Nduati
Lancet 01)
Petra Trial,
Tanzania, South
Africa, Uganda
(Petra Group
Lancet 02)
Retro-CI Trial,
Coˆte d’Ivoire
(Wiktor Lancet 99)
Vitamin A Trial,
South Africa
(Coutsoudis
Lancet 99)
Mother-infant pairs 401 104 197 1458 261 660
Follow-up (days), median (IQR) 550 (303–639) 542 (293–589) 729 (332–849) 548 (388–554) 730 (290–1008) 300 (128–456)
Maternal Age (years), mean (SD) 25.6 (5.3) 24.5 (5.0) 23.9 (4.4) 27.0 (8.1) 26.4 (5.2) 26.2 (4.7)
Antenatal maternal CD4, median (IQR) 541 (359–741) 524 (384–768) 392 (262–530) 449 (295–630) 549 (354–726) 440 (311–597)
Maternal death, n (%) 18 (4.5) 9 (8.7) 17 (8.6) 61 (4.2) 9 (3.4) 5 (0.8)
Child age at maternal death (days),
median (IQR)
274 (80–561) 342 (97–379) 240 (171–413) 341 (234–441) 142 (128–319) 229 (13–232)
Male child, n (%) 207 (51.6) 49 (47.2) 96 (48.7) 726 (49.9) 131(50.2) 317 (50.3)
Birthweight,2.5 kg, n (%) 62 (15.5) 18 (17.3) 13 (6.6) 96 (6.6) 27 (10.3) 74 (11.2)
Child ever breastfed, n (%) 401 (100.0) 104 (100.0) 197 (100.0) 1397 (95.8) 261 (100.0) 452 (68.5)
Breastfeeding duration (days), median
(IQR)
274 (183–295) 342 (231–484) 398 (152–548) 212 (69–420) 458 (336–559) 90 (30–278)
Child death, n (%) 88 (22.0) 26 (25.0) 45 (22.8) 184 (12.6) 39 (14.9) 49 (7.4)
Child age at death (days), median (IQR) 202 (88–429) 175 (54–505) 247 (122–366) 171 (82–293) 101 (4–339) 86 (36–153)
HIV-infected child, n (%) 89 (24.0) 14 (16.5) 59 (30.9) 253 (18.1) 68 (27.2) 143 (22.8)
Peri-partum HIV infection, n 38 1 27 110 41 111
Postnatal HIVinfection, n 22 5 19 87 23 22
Unknown timing of HIV infection, n 29 8 13 56 4 10
doi:10.1371/journal.pone.0028510.t001
Table 2. Characteristics of the mother-infant pairs included in the pooled analysis (second generation studies, after year 2000).
VTS Cohort,
South Africa
(Coovadia
Lancet 07)
Zvitambo
Trial, Zimbabwe
(Humphrey
JID 06)
ANRS Ditrame
Plus Cohort, Coˆte
d’Ivoire (Becquet
PloS Med 07)
Good Start
Cohort, South
Africa (Doherty
AIDS 07)
Mashi Trial,
Botswana (Thior
JAMA 06)
Mitra Plus
Cohort, Tanzania
(Kilewo JAIDS 09)
Mother-infant pairs 1430 4548 747 665 1200 441
Follow-up (days), median (IQR) 583 (178–741) 456 (324–704) 730 (467–734) 252 (140–252) 1096 (725–1461) 730 (547–732)
Maternal Age (years), mean (SD) 25.5 (7.2) 25.0 (5.0) 27.1 (5.3) 25.4 (5.2) 27.6 (5.4) 27.0 (4.8)
Antenatal maternal CD4, median (IQR) 456 (313–626) 400 (259–570) 392 (251–561) Not available 364 (234–514) 416 (267–579)
Maternal death, n (%) 71 (4.9) 246 (5.4) 13 (1.7) 20 (3.0) 39 (3.2) 9 (2.0)
Child age at maternal death (days),
median (IQR)
473 (221–760) 285 (113–503) 291 (123–424) 141 (72–162) 472 (128–849) 354 (132–435)
Male child, n (%) 711 (50.4) 2235 (49.1) 378 (50.6) 328 (49.9) 554 (47.0) 225 (51.0)
Birthweight,2.5 kg, n (%) 157 (11.0) 776 (17.1) 94 (12.6) 96 (14.4) 94 (7.8) 59 (13.4)
Child ever breastfed, n (%) 1262 (88.2) 4186 (92.0) 434 (58.1) 259 (39.0) 592 (59.3) 441 (100.0)
Breastfeeding duration (days),
median (IQR)
204 (109–279) 389 (274–528) 124 (96–204) 140 (112–168) 176 (118–183) 175 (140–182)
Child death, n (%) 201 (14.1) 885 (19.5) 79 (10.6) 67 (10.1) 114 (9.5) 35 (7.9)
Child age at death (days), median (IQR) 123 (62–305) 126 (80–301) 68 (1–204) 84 (35–140) 139 (28–284) 238 (175–361)
HIV-infected child, n (%) 249 (20.2) 1341 (30.1) 58 (7.8) 122 (24.8) 87 (7.4) 26 (5.9)
Peri-partum HIV infection, n 127 728 40 68 56 16
Postnatal HIV infection, n 70 257 18 23 27 8
Unknown timing of HIV infection, n 52 356 0 31 4 2
doi:10.1371/journal.pone.0028510.t002
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estimate would thus need to be interpreted in the light of the
selection that occurs with children at risk of postnatal infection by
definition being those who survived without infection the neonatal
period which is one of high mortality risk. On the other hand,
perinatally infected children will have to survive this risky period
with the infection as an added exposure. However, there is no
evidence of an increased neonatal mortality risk associated with
perinatal infection [25]. Further, complementary analyses on the
same dataset showed that differences seen in the survival of
perinatally or postnatally infected children cannot be explained by
differences in background mortality, which is much higher in the
neonatal period [26]. We suggest that our findings are explained
by the immunological immaturity, and thus reduced virological
control, of the fetus and new-born at the time of acquisition of
infection whereas postnatal acquisition of infection in infants who
are more immunologically mature would be associated with a
greater chance of survival [27].
We further also confirm the impact of both maternal health, as
measured by her HIV immunological progression, and vital status on
infant survival. Two-year infant mortality adjusted risk was one third
higher among women with ante-partum CD4 count ,350 cells/ml
than among those with mothers a CD4 count above this threshold;
and it was two times higher when the mother had died during the two
years post-partum than when the mother was alive two years after
birth. Lifelong antiretroviral treatment was not available to women
followed-up in all studies selected for this pooled analysis but one. By
lack of statistical power, it was therefore not possible to assess the
impact of maternal antiretroviral treatment on the survival of
children. Bearing in mind that maternal health is an important
confounder of child survival, it would be crucial to investigate
whether there is a positive impact of such a maternal treatment on
infant survival. As maternal antiretroviral treatment keeps an infected
mother alive, there would be an indirect effect of reducing child
mortality in both her HIV-infected and uninfected children.
Table 3. Mortality rate per 1000 child-years of follow-up by selected maternal and infant characteristics (n = 12,112).
Number (n=12,112) Deaths (n =1,812)
Mortality rate per 1000 child-
years of follow-up
Location
Southern Africa 9270 (76.5) 1384 105.8
Eastern Africa 1329 (11.0) 196 100.1
Western Africa 1513 (12.5) 232 100.0
Maternal PMTCT ARV
None 6634 (54.8) 1179 149.2
sdNVP 1657 (13.7) 223 99.3
2 or 3 drugs regimen 3821 (31.5) 410 56.8
Infant PMTCT ARV
None 6892 (46.9) 1227 141.9
sdNVP +/2 ZDV/3TC 5220 (53.1) 585 67.1
Maternal CD4 count
,350 3973 (32.8) 796 135.2
$350 6605 (54.5) 776 77.2
Unknown 1534 (12.7) 240 167.7
Maternal vital status
Mothers known alive 11595 (95.7) 1598 95.6
Mothers known dead 517 (4.3) 214 332.3
Sex of the infant
Girls 5957 (49.2) 883 103.5
Boys 6072 (50.1) 918 104.3
Unknown 83 (0.7) 11 -
Infant birthweight
,2.5 kg 1566 (12.9) 445 232.4
$2.5 kg 10372 (85.6) 1333 87.3
Unknown 174 (1.5) 34 -
Breastfeeding status
Never 2126 (17.5) 310 113.9
Ever 9986 (82.5) 1502 102.6
Child infection status
HIV-uninfected 8964 (74.0) 562 39.3
HIV-infected 2509 (20.7) 1096 381.6
Unknown 639 (5.3) 154 -
doi:10.1371/journal.pone.0028510.t003
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We present estimates of risk of mortality in children born to
HIV-infected mothers in Africa, on the basis of a large dataset with
wide variations in the characteristics of the patients included in the
meta-analysis. The individual meta-analysis and adjustments in
the model account for some of these effects. We acknowledge that
there may have been confounding factors that had not been taken
into account by our design, but we consider that the most
important ones were controlled for. Additionally, the science in the
prevention of mother-to-child transmission of HIV has changed
since the time of the studies included in this meta-analysis.
Expanding the indication of use of potent antiretroviral drug
combinations to all pregnant, delivering, and breast-feeding HIV-
infected women is now seen as an unprecedented opportunity to
radically reduce the burden of paediatric AIDS [28]. The
implication of this on the predicted trends in child mortality will
need to be carefully assessed in future studies.
Our findings draw attention to the importance of comprehensive
care for HIV-infected women. More specifically, our results stress
the urgency of providing optimal antiretroviral treatment to women
who need it for their own health (e.g. with ante-partum CD4 count
,350 cell/ml according to the newly revised WHO guidelines [29])
to also improve survival of their (infected and uninfected) children.
Maternal antiretroviral treatment will radically reduce the burden
of paediatric HIV worldwide, and contribute to the improvement of
survival of children born to HIV-infected women in improving
maternal health and considerably lowering the risk of maternal
death [30]. Moreover, there is still an urgent need for the effective
prevention of mother-to-child transmission of HIV through
breastfeeding: even postnatally infected children are three-times
more likely to die than uninfected children. These findings also
highlight the urgent need for the early assessment of HIV infection
in HIV-exposed children to allow the timely initiation of
antiretroviral care and support for HIV-infected children. Finally,
these revised estimates of infant survival by timing of acquisition of
HIV infection will now be used by UNAIDS to improve forecasts of
the future of the HIV pandemic [31].
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